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Abstract—7-Deoxypaclitaxel, 10-deacetoxypaclitaxel and 10-deacetoxy-7-deoxypaclitaxel were prepared and evaluated for their ability 
to promote assembly of tubulin into microtubules, their cytotoxicity against NCI/ADR-RES cells and for their interactions with P-
glycoprotein in bovine brain microvessel endothelial cells.  The three compounds were essentially equivalent to paclitaxel in cytotoxicity 
against NCI/ADR-RES cells.  They also appeared to interact with P-glycoprotein in the endothelial cells with the two 10-deacetoxy 
compounds having less interaction than paclitaxel and 7-deoxypaclitaxel.  ©2000 Elsevier Science Ltd. All rights reserved. 
Paclitaxel (1, Fig. 1), a cytotoxic agent from the bark of 
the Pacific yew (Taxus brevifolia),1 exerts its activity by 
altering tubulin dynamics.2  Paclitaxel, as well as its 
semisynthetic analogue docetaxel (2, Fig. 1), are effective 
agents for the treatment of ovarian and breast cancer, 
Kaposi's sarcoma, and non-small cell lung cancer.3  
However, the continued evaluation of new analogues is 
important, because drug resistance has developed, and 
paclitaxel, like many other anticancer agents, does not 
cross the blood-brain barrier (BBB).  Active efflux by P-
glycoprotein (Pgp) is believed to be responsible for the 
lack of brain uptake of many anticancer drugs, leaving 
brain cancer patients with few viable treatment options.4,5  
Paclitaxel's limited oral bioavailability, lack of 
accumulation in brain tissues, and efficacy in brain tumors 
has been attributed to active efflux by Pgp.6,7  In our 
efforts to develop paclitaxel analogues that can cross the 
BBB,8 we are studying the influence of chemical 
modifications of paclitaxel on Pgp in the BBB and are now 
reporting new results concerning structure-efflux 
relationships of paclitaxel analogues. 
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Figure 1.  Structures of paclitaxel (1, R1 = Ph, R2 = Ac) and docetaxel (2, 
R1 = O-tert-Bu, R2 = H). 
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A comparison of the structural features of over one 
hundred known substrates and modulators for Pgp 
suggested that clusters of hydrogen bond acceptors 
(electron donating groups), arranged in fixed spatial 
distances from each other, are required for recognition by 
Pgp binding sites.9-11  The recognition elements are formed 
either by two or by three electron donating groups.  It was 
also hypothesized that the number and strength of the 
hydrogen bonds present in a molecule determine Pgp 
affinity.  This implies that one could remove recognition 
elements from the molecule that are not necessary for 
biological activity and improve activity against multi-drug 
resistant cancers and achieve BBB penetration.   
 
We analyzed paclitaxel for Pgp recognition patterns and 
determined six relevant hydrogen bond acceptor groups 
(Fig. 2).  Groups 1-4 (Fig. 2) are so-called type I units that 
are formed by two hydrogen bond acceptor groups (A or a) 
with a spatial separation of 2.5 + 0.3 Å.  Strong electron 
donating groups, containing oxygens are denoted as “A” 
and less potent donors such as tertiary amines, halides, 
sulfides or -electron donating groups as “a”.  In addition, 
two so-called type II units, groups 5 and 6, were identified.  
Type II units are formed either by two hydrogen bond 
acceptor groups with a spatial separation of 4.6 + 0.6 Å 
(group 5: AA (1.5) pattern between the 7-hydroxyl and the 
5-ether group of the oxetane moiety) or by three hydrogen 
bond acceptor groups separated from each other by 2.5 + 
0.3 A, with the outer two acceptor groups at a distance of 
4.6 + 0.6 Å (group 6: AAA (1.4.6) relationship between 
the C9 carbonyl and the C10 acetate).  The type I units are 
found in all Pgp substrates and type II units are present in 
all Pgp inducers and many Pgp substrates.   
 
According to structure-activity relationship studies, neither 
the C7 hydroxy group nor the C10 acetyl group are 
essential for bioactivity.12  Substitution at C7 and C10 is 
well tolerated,12 and it has been demonstrated that these 
regions of the molecule are important for Pgp affinity.13  
Ojima and collaborators have shown that specific 
modifications at the C10 position (i. e. propionate instead 
of acetate at O10) of 3’-dephenyl-3’-isobutylpaclitaxel and 
related analogues resulted in a significant increase in 
cytotoxicity, especially against NCI/ADR-RES cells, 
expressing the MDR (multi-drug resistant) phenotype.  
This result was ascribed to an effective inhibition of 
binding to Pgp by these analogues.13  The effects are 
complex, however, and replacement of the 10-acetate with 
a 10-propionate group in paclitaxel does not lead to an 
increase in cytotoxicity against MDR-expressing cancer 
cells.14  In another example, we have recently shown that 
Tx-67, a paclitaxel analogue, carrying a 10-O-succinyl 
monoester moiety, is able to evade Pgp-mediated efflux 
and can permeate the BBB in vitro and in situ.8  Of interest 
in this context are also recent reports, disclosing that TXD-
258 (7-O-methyl-10-O-methyldocetaxel) is able to cross 
the BBB, and that RPR-109881A (a 7,8-cyclopropyl 
docetaxel analogue) is effective against MDR-positive and 
taxane resistant human tumor xenografts.15 
 
Based on these previous observations, we decided to 
explore additional chemical modifications of the putative 
group 5 and 6 paclitaxel recognition elements with the 
goal to decrease the strength for Pgp binding and thereby 
improve activity against MDR cancer cells and enhance 
BBB permeation.  We therefore prepared and evaluated 
paclitaxel analogues lacking the C7 hydroxy group and/or 
C10 acetoxy groups. 
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Figure 2. Analysis of paclitaxel for type I (1.3 and 1.5) and type II (1.4.6) 
interaction sites with Pgp.   
 
10-Deacetoxypaclitaxel was prepared in one step via 
samarium diiodide-mediated deoxygenation.16,17  Treatment 
of paclitaxel (1) with SmI2 and acetic acid provided 10-
deacetoxypaclitaxel (3) in 91% yield (Scheme 1). 
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Scheme 1. a) SmI2, AcOH (91%). 
 
7-Deoxypaclitaxel was prepared, employing the Barton 
deoxygenation reaction, as previously described by the 
Kingston group (Scheme 2).18  Treatment of paclitaxel (1) 
with tert-butyldimethylsilyl chloride, imidazole and 4-
(dimethylamino)pyridine furnished 2’-(tert-
butyldimethylsilyl)paclitaxel (4) in 85% yield.  Compound 
4 was treated with 2.2 equiv of sodium hydride in dry 
THF, then excess carbon disulfide and iodomethane to 
provided 5 in 65% yield. Treatment of 5 with tributyltin 
hydride and AIBN in toluene at 80 C, followed by 
deprotection of 2’-(tert-butyldimethylsilyl) yielded 7-
deoxypaclitaxel (6) in 48% from 5. 
 
In the course of these studies, we also developed an 
efficient method to convert paclitaxel into 10-deacetoxy-7-
deoxypaclitaxel (7, Scheme 2).  Treatment of 7-
deoxypaclitaxel (6) with SmI2 in the presence of AcOH 
furnished 7 in 82% yield.  This method is superior to one 
reported earlier for the synthesis of 7, which produced a 
low overall yield (5%).19 
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Scheme 2. a) TBSCl, imidazole, DMAP, DCM (85%); b) NaH, CS2, MeI, 
THF (65%); c) AIBN, Bu3SnH, PhH; then HF-Py, Py (48% overall);  
d) SmI2, AcOH (82%). 
 
Table 1. Biological Evaluation of Deoxypaclitaxel 
Analogues in a Tubulin Assembly Assay and for 
Antiproliferative Activity Against MCF7 and NCI/ADR-
RES Cell Lines.14 
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Cmpd.21 R1 R2 MTa  MCF7b 
 
NCI/ 
ADR- 
RESc 
3 H OH 2.2 0.87 0.79 
6 OAc H 1.4 30.0 1.0 
7 H H 2.0 9.0 0.21 
 
aMicrotubule assembly ED50/ED50(Paclitaxel); 
bMCF7ED50/ED50(Paclitaxel);  
cNCI/ADR-RES22 ED50/ED50(Paclitaxel). 
 
The three deoxygenated analogues 3, 6 and 7 were tested 
in a tubulin assembly assay and as inhibitors of 
proliferation against the MCF7 and NCI/ADR-RES breast 
cancer lines (Table 1).14  In the tubulin assembly assay 
analogue 6 was just slightly less active than paclitaxel, 
while 3 and 7 were about half as active as paclitaxel.  
Compound 3 had activity similar to paclitaxel against 
MCF7 proliferation but 6 and 7 had significantly reduced 
activity.  Differences between the three analogues and 
paclitaxel against the resistant cell line NCI/ADR-RES 
were minimal.  In a previous report it was found that 3 and 
6 had essentially the same cytotoxicity as paclitaxel 
against HCT 116 cells while 7 was slightly less active.19,20 
 
We assessed the analogues for rhodamine 123 uptake into 
bovine brain microvessel endothelial cells (BMECs).8  The 
intracellular concentration of rhodamine 123, itself a 
substrate for Pgp, is enhanced by compounds that compete 
for binding with Pgp in BMECs.  Analogues 3, 6 and 7 
were compared to paclitaxel at two concentrations and to 
cyclosporin A, as positive controls (Fig. 3).  All 
compounds increased the level of rhodamine 123 uptake 
indicating that they interact with Pgp.  At 5 M, 
compounds 3 and 7 interacted less than paclitaxel and 6. 
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Figure 3.  Rhodamine 123 (5 M) uptake into BMECs alone (Con = 
control) and in the presence of cyclosporin A (CsA) at 5 M, and 
paclitaxel (Tx) and paclitaxel analogues 3, 6, and 7 at 10 M and 5 M.8 
 
The lack of large differences between paclitaxel, 3, 6, and 
7 as cytotoxic agents against NCI/ADR-RES cells indicate 
that removal of the group 5 and 6 (type II) recognition 
elements in paclitaxel did not reduce interactions between 
the paclitaxel analogues and Pgp in the MDR cancer cell 
line.  Apparently, the interactions of the remaining group 
1-4 recognition elements of the paclitaxel analogues 3, 6, 
and 7 with Pgp are sufficient enough for effective binding 
to cause efflux from MDR cancer cells.   
 
The effect in BMECs is concentration dependent.  
Paclitaxel and the three analogues increased rhodamine 
123 uptake into BMECs at 10 M.  However, at 5 M, 
compounds 3 and 7, which both lack the C10 acetoxy 
group, had reduced uptake of rhodamine 123 in 
comparison to paclitaxel and compound 6, which lacks the 
C7 hydroxyl group but carries the C10 acetoxy group.  
The results demonstrate the importance of the group 6 
recognition element for paclitaxel interaction with Pgp in 
BMECs.  Compounds 3 and 7 are nevertheless substrates 
for Pgp because uptake of rhodamine 123 is increased in 
comparison to the rhodamine 123 control.  As was the case 
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with the MDR cancer cell line, the group 1-4 recognition 
elements are sufficient to increase rhodamine 123 uptake 
in comparison to the control.  Overall, our original 
hypothesis, that removal of Pgp recognition elements 
could decrease the strength for Pgp binding, was verified, 
because rhodamine 123 uptake was clearly reduced for 
compounds 3 and 7 in BMEC’s. 
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